EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
Inc. (NASDAQ:TTWO) stock has reached a 52-week high, soaring to $192.32, marking a significant milestone for the $33.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback